Cutaneous melanomas associated with nevi
Phase 2: Introduce AOD 9604 (weeks 5-8) Once tirzepatide is tolerated at the initial dose, add AOD 9604 at 250mcg daily
Another potential therapeutic, Minocycline is a microglial inhibitor which reduces BBB dysfunction by preventing production of glutamate, matrix metalloproteinases, and the proinflammatory cytokine, IL-1, and increasing the levels of cells responsible for the remyelination of neurons which would be relevant in treating AD [138, 140,141,142]
Demand for GLP-1 therapies is likely to increase with the availability of oral forms
Environmental Toxin Panel What it measures: Urinary markers for glyphosate, phthalates, BPA, and other industrial chemicals